BUSINESS COMBINATIONS (Details 2)	3 Months Ended			0 Months Ended		12 Months Ended					12 Months Ended				12 Months Ended				12 Months Ended				12 Months Ended			12 Months Ended												0 Months Ended		3 Months Ended				3 Months Ended
	Mar. 31, 2013 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2012 USD ($)	Jun. 18, 2012 OraPharma USD ($)	Mar. 31, 2013 OraPharma Developed Markets USD ($)	Dec. 31, 2012 Other Business Combinations USD ($)	Mar. 31, 2013 Other Business Combinations USD ($)	Dec. 31, 2012 Other Business Combinations Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Measurement Period Adjustments USD ($)	Mar. 31, 2013 Other Business Combinations Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2012 Other Business Combinations Product brands	Dec. 31, 2012 Other Business Combinations Product brands Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Product brands Measurement Period Adjustments USD ($)	Mar. 31, 2013 Other Business Combinations Product brands Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2012 Other Business Combinations Corporate brands	Dec. 31, 2012 Other Business Combinations Corporate brands Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Corporate brands Measurement Period Adjustments USD ($)	Mar. 31, 2013 Other Business Combinations Corporate brands Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2012 Other Business Combinations Product rights	Dec. 31, 2012 Other Business Combinations Product rights Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Product rights Measurement Period Adjustments USD ($)	Mar. 31, 2013 Other Business Combinations Product rights Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2012 Other Business Combinations Royalty agreement	Dec. 31, 2012 Other Business Combinations Royalty agreement Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Royalty agreement Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2012 Other Business Combinations Partner relationships	Dec. 31, 2012 Other Business Combinations Partner relationships Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 31, 2013 Other Business Combinations Partner relationships Amounts Recognized (as adjusted) USD ($)	Oct. 02, 2012 Johnson & Johnson Consumer Companies Inc USD ($)	Sep. 28, 2012 Johnson & Johnson North America USD ($)	Sep. 24, 2012 QLT Inc. and QLT Ophthalmics, Inc. USD ($)	Sep. 24, 2012 QLT Inc. and QLT Ophthalmics, Inc. Outside the U.S. USD ($)	Sep. 24, 2012 QLT Inc. and QLT Ophthalmics, Inc. U.S USD ($)	May 23, 2012 University Medical Pharmaceuticals USD ($)	Mar. 31, 2013 Atlantis USD ($)	May 02, 2012 Atlantis USD ($)	May 02, 2012 Atlantis MXN	Mar. 13, 2012 Gerot Lannach USD ($)	Mar. 13, 2012 Gerot Lannach EUR (€)	Mar. 31, 2013 Probiotica USD ($)	Mar. 31, 2013 Probiotica BRL	Feb. 01, 2012 Probiotica USD ($)	Feb. 01, 2012 Probiotica BRL	Mar. 31, 2013 Probiotica Minimum	Mar. 31, 2013 Probiotica Maximum
Business Combinations
Upfront payment				$ 289,300,000																												$ 50,000,000	$ 62,500,000	$ 65,000,000		$ 65,500,000	847,300,000	$ 164,000,000	€ 125,000,000
Payment of assumed debt				37,900,000
Series of potential milestones to be paid				114,000,000																											20,000,000			40,000,000		8,900,000	114,700,000	19,700,000	15,000,000
Fair value of contingent consideration				99,200,000		44,200,000																									7,900,000			1,500,000		7,600,000		16,800,000
Period of exclusive supply agreement																																						10 years	10 years
Percentage of sales relating to the acquired assets																																						90.00%	90.00%
Assets acquired and liabilities assumed
Cash and cash equivalents								7,255,000	(258,000)	6,997,000
Accounts receivable								29,846,000	(17,000)	29,829,000
Assets held for sale								15,566,000		15,566,000
Inventories								64,819,000	(8,091,000)	56,728,000
Other current assets								2,524,000		2,524,000
Property, plant and equipment								9,027,000		9,027,000
Identifiable intangible assets, excluding IPR&D								666,619,000	1,527,000	668,146,000		456,720,000	(1,325,000)	455,395,000		31,934,000	3,725,000	35,659,000		109,274,000	(873,000)	108,401,000		36,277,000	36,277,000		32,414,000	32,414,000
Acquired IPR&D	555,386,000		546,876,000					1,234,000		1,234,000
Indemnification assets								27,901,000		27,901,000
Other non-current assets								21,000		21,000
Current liabilities								(32,146,000)	(350,000)	(32,496,000)
Long-term debt, including current portion								(920,000)		(920,000)
Liability for uncertain tax position								(6,682,000)	6,682,000
Other non-current liabilities								(28,523,000)		(28,523,000)
Deferred income taxes, net								(10,933,000)	373,000	(10,560,000)
Total identifiable net assets								745,608,000	(134,000)	745,474,000
Goodwill					120,100,000			70,600,000	(8,587,000)	62,013,000
Total fair value of consideration transferred				388,500,000		807,500,000		816,208,000	(8,721,000)	807,487,000																			41,700,000	107,300,000												90,500,000	158,000,000
Fair value of trade accounts receivable acquired							29,800,000
Gross contractual amount of trade accounts receivable acquired							31,100,000
Expected uncollectible of trade accounts receivable acquired							1,300,000
Estimated weighted-average useful life						10 years					10 years				12 years				10 years				9 years			5 years
Time restriction of contractual arrangement dependent on nature of claim																																												2 years	5 years
Acquisition-related costs	7,899,000	7,505,000
Acquisition-related contingent consideration	(2,185,000)	9,839,000
Other disclosures
Amounts classified as Restricted																																			8,000,000
Purchase price has been placed in escrow in accordance with the indemnification provisions																																								$ 12,900,000	22,500,000
Percentage of purchase price that has been placed in escrow in accordance with the indemnification provisions																																								50.00%	50.00%
Period of escrow account																																								2 years	2 years